Literature DB >> 26314689

An aptamer targeting shared tumor-specific peptide antigen of MAGE-A3 in multiple cancers.

Chin-Yu Wang1, Bai-Ling Lin1, Chung-Hsuan Chen1.   

Abstract

A DNA aptamer was identified against the shared tumor-specific MAGE-A3111-125 peptide antigen. The dissociation constant between the aptamer and the peptide was measured at 57 nM. Binding of the aptamer to seven types of cancer cells, melanoma, breast, colorectal, liver, lung, pancreas and oral cancer, was confirmed with flow cytometry and fluorescence imaging. Cy3-conjugated aptamers signals were specifically localized to the surface of those cancer cells. The results indicate that the DNA aptamer against the shared tumor-specific MAGE-A3 peptide can be used in cancer cell targeting and has the potential for developing into new modalities for the diagnosis of multiple cancers.
© 2015 UICC.

Entities:  

Keywords:  SELEX; aptamer; shared tumor-specific antigen

Mesh:

Substances:

Year:  2015        PMID: 26314689     DOI: 10.1002/ijc.29826

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

Review 1.  Emerging cancer-specific therapeutic aptamers.

Authors:  Sorah Yoon; John J Rossi
Journal:  Curr Opin Oncol       Date:  2017-09       Impact factor: 3.645

2.  MAGE-TRIM28 complex promotes the Warburg effect and hepatocellular carcinoma progression by targeting FBP1 for degradation.

Authors:  X Jin; Y Pan; L Wang; L Zhang; R Ravichandran; P R Potts; J Jiang; H Wu; H Huang
Journal:  Oncogenesis       Date:  2017-04-10       Impact factor: 7.485

3.  Next-Generation Cancer-Specific Hybrid Theranostic Nanomaterials: MAGE-A3 NIR Persistent Luminescence Nanoparticles Conjugated to Afatinib for In Situ Suppression of Lung Adenocarcinoma Growth and Metastasis.

Authors:  Ming-Hsien Chan; Wen-Tse Huang; Jing Wang; Ru-Shi Liu; Michael Hsiao
Journal:  Adv Sci (Weinh)       Date:  2020-03-14       Impact factor: 16.806

4.  Development of Aptamer-Based TID Assays Using Thermophoresis and Microarrays.

Authors:  Tracy Kurth; Sandra Witt; Svenja Bolten; Janice-Joy Waniek; Carlotta Kortmann; Antonina Lavrentieva; Thomas Scheper; Johanna-Gabriela Walter
Journal:  Biosensors (Basel)       Date:  2019-10-14

5.  Selection and preliminary application of a single stranded DNA aptamer targeting colorectal cancer serum.

Authors:  Kun Li; Liqing Qi; LiMing Gao; Ming Shi; Jian Li; ZhiWei Liu; Lu Zhao
Journal:  RSC Adv       Date:  2019-11-27       Impact factor: 4.036

6.  Targeted drug delivery using an aptamer against shared tumor-specific peptide antigen of MAGE-A3.

Authors:  Chin-Yu Wang; Bai-Ling Lin; Chung-Hsuan Chen
Journal:  Cancer Biol Ther       Date:  2020-11-29       Impact factor: 4.742

7.  LINC01234/MicroRNA-31-5p/MAGEA3 Axis Mediates the Proliferation and Chemoresistance of Hepatocellular Carcinoma Cells.

Authors:  Yunhao Chen; Hui Zhao; Haibo Li; Xiao Feng; Hui Tang; Chunhui Qiu; Jianwen Zhang; Binsheng Fu
Journal:  Mol Ther Nucleic Acids       Date:  2019-11-13       Impact factor: 8.886

Review 8.  Aptamers: a novel targeted theranostic platform for pancreatic ductal adenocarcinoma.

Authors:  Q Li; S H Maier; P Li; J Peterhansl; C Belka; J Mayerle; U M Mahajan
Journal:  Radiat Oncol       Date:  2020-08-05       Impact factor: 3.481

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.